



**Christina Bryan**

Vice President of  
External Affairs

**Beebe Healthcare**

David A. Tam,  
MD, MBA  
President & CEO  
DHA Board Chair

**ChristianaCare**

Janice E. Nevin, MD,  
MPH  
President & CEO  
DHA Board Vice Chair

**Bayhealth**

Terry Murphy  
President & CEO  
DHA Board Secretary  
& Treasurer

**Nemours  
Children's Health**

Mark Marcantano  
President  
Delaware Valley  
Operations

**TidalHealth  
Nanticoke**

Penny Short, MSM,  
BSN, RN President

**Saint Francis  
Hospital**

Marlow Levy, RN, MBA,  
FACHE  
President

**Delaware  
Healthcare  
Association**

Brian W. Frazee  
President & CEO

January 28, 2025

The Honorable Kim Williams  
411 Legislative Ave  
Dover, DE 19901

**RE: Support for banning Tianeptine (HB 21)**

Dear Representative Williams,

The Delaware Healthcare Association, representing Delaware's hospitals, health systems, and related healthcare organizations, is pleased to support House Bill 21.

House Bill 21 classifies Tianeptine as a schedule 1 controlled substance and bans its sale in Delaware.

Tianeptine is not approved by the U.S. Food and Drug Administration for any medical use. Still, products containing tianeptine are being illegally marketed for having positive health impacts when just the opposite is true. Tianeptine misuse has been linked to severe adverse health effects including respiratory depression, seizures, severe sedation, and even death. We support HB 21 as a step to prevent unnecessary negative health impacts and hospitalizations in Delaware.

Thank you for the opportunity to share DHA's support for HB 21. We look forward to working with you and your colleagues in the General Assembly to advance this legislation.

Sincerely,

A handwritten signature in blue ink that reads 'Christina Bryan'.

Christina Bryan  
Vice President of External Affairs